Literature DB >> 8957747

The effect of long-term prednisone treatment on growth hormone and insulin-like growth factor-1.

M F Prummel1, W M Wiersinga, H Oosting, E Endert.   

Abstract

Due to a lack of longitudinal data the precise effect of long-term corticosteroid treatment on serum levels of the anabolic hormones Growth Hormone (GH) and Insulin-like Growth Factor-1 (IGF-1) is unknown. Therefore, we prospectively followed GH and IGF-1 levels over a six month period in 18 euthyroid patients with Graves' ophthalmopathy. Ten patients were treated with a three month course of prednisone; eight patients receiving retrobulbar irradiation served as controls. Baseline serum GH and IGF-1 levels were similar in both groups. Whereas no changes were seen in controls, prednisone induced a rapid increase in serum IGF-1 levels, which was sustained during the entire treatment period: 18.2 +/- 5.2 at baseline vs 24.1 +/- 6.7 nmol/l after 12 weeks of treatment (p < 0.001). After discontinuation of prednisone IGF-1 returned to baseline levels. Basal GH levels were frequently undetectable, but during treatment GH values were lower in the prednisone group (median of detectable values 4.0 mU/L [range 2.0-26.0]) than in controls (11.8 [2.8-44.0]; p < 0.01). In conclusion, long-term prednisone treatment is associated with suppressed GH levels and with an increase in total IGF-1 levels. This suggests that prednisone can disrupt the GH/IGF 1 axis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957747     DOI: 10.1007/bf03349028

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  18 in total

1.  Divergent effects of short term glucocorticoid excess on the gonadotropic and somatotropic axes in normal men.

Authors:  J D Veldhuis; G Lizarralde; A Iranmanesh
Journal:  J Clin Endocrinol Metab       Date:  1992-01       Impact factor: 5.958

2.  Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay.

Authors:  R W Furlanetto; L E Underwood; J J Van Wyk; A J D'Ercole
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

3.  Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects.

Authors:  A Giustina; M Doga; C Bodini; A Girelli; F Legati; S Bossoni; G Romanelli
Journal:  Acta Endocrinol (Copenh)       Date:  1990-02

Review 4.  Glucocorticoid-induced osteoporosis: pathogenesis and management.

Authors:  B P Lukert; L G Raisz
Journal:  Ann Intern Med       Date:  1990-03-01       Impact factor: 25.391

Review 5.  Physiological role of the insulin-like growth factor binding proteins.

Authors:  J Zapf
Journal:  Eur J Endocrinol       Date:  1995-06       Impact factor: 6.664

Review 6.  Corticosteroids and growth.

Authors:  R N Fine
Journal:  Kidney Int Suppl       Date:  1993-10       Impact factor: 10.545

7.  Serum somatomedin/insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushing's syndrome or receiving glucocorticoid therapy.

Authors:  M Gourmelen; F Girard; M Binoux
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

8.  Insulin-like growth factor 1 and bone turnover in glucocorticoid-treated and control subjects.

Authors:  I R Reid; P D Gluckman; H K Ibbertson
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

9.  Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure.

Authors:  M A Magiakou; G Mastorakos; M T Gomez; S R Rose; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

10.  Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids.

Authors:  C P Sanchez; W G Goodman; D Brandli; M Goldenhersh; C Murray; E Carlton; T Hahn; I B Salusky
Journal:  J Bone Miner Res       Date:  1995-01       Impact factor: 6.741

View more
  7 in total

Review 1.  Pre-analytic considerations for the proper assessment of hormones of the hypothalamic-pituitary axis in epidemiological research.

Authors:  Rachel L Derr; Scott J Cameron; Sherita Hill Golden
Journal:  Eur J Epidemiol       Date:  2006       Impact factor: 8.082

2.  Dexamethasone does not increase IGF-I and IGFBP-3 levels in man in the absence of endogenous GH.

Authors:  F E Finamor; A M Lengyel
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

3.  Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3.

Authors:  P Sarzi-Puttini; F Atzeni; J Schölmerich; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

4.  Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study.

Authors:  Gitte Vrelits Sørensen; Deirdre P Cronin-Fenton; Henrik Toft Sørensen; Sinna Pilgaard Ulrichsen; Lars Pedersen; Timothy L Lash
Journal:  Breast Cancer Res       Date:  2012-02-03       Impact factor: 6.466

Review 5.  Insulin Peptides as Mediators of the Impact of Life Style in Alzheimer's disease.

Authors:  A M Fernandez; A Santi; I Torres Aleman
Journal:  Brain Plast       Date:  2018-12-12

6.  Pre- and postdiagnosis growth failure, adult short stature, and untreated growth hormone deficiency in radiotherapy-treated long-term survivors of childhood brain tumor.

Authors:  Julia Anttonen; Tiina Remes; Pekka Arikoski; Päivi Lähteenmäki; Mikko Arola; Arja Harila-Saari; Tuula Lönnqvist; Tytti Pokka; Pekka Riikonen; Kirsti Sirkiä; Heikki Rantala; Marja Ojaniemi
Journal:  PLoS One       Date:  2022-09-06       Impact factor: 3.752

7.  Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study.

Authors:  Inga-Lill Engvall; Björn Svensson; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2008-11-05       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.